To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

Nanobodies, also known as single-domain antibodies (sdAbs) or VHH antibodies, are only 1/10th the size of traditional monoclonal antibodies but can retain full antigen-binding potential, establishing ...